Corporate Leadership

What is in scope

Chief Executive Officers of major Fortune 500 firms across sectors — defence and aerospace contractors, technology platforms, commercial banks, automakers, retailers, healthcare conglomerates. The dataset's coverage at present is concentrated in US-listed firms; expansion to FTSE 100 and DAX equivalents is on the roadmap. Pharmaceutical-company CEOs sit in the pharmaceutical domain and are not duplicated here.

Why this domain matters

Corporate-leadership selection is the dataset's most directly mechanism-traceable category. The board of directors at a large publicly listed firm selects the CEO, with substantial governance influence from large institutional shareholders. Two of those shareholders — BlackRock and Vanguard — together hold the largest share-of-vote at most US Fortune 500 firms and have published proxy-voting policies that since the late 2010s have voted against directors at companies whose boards lacked gender diversity. The Goldman Sachs 2020 IPO-diversity rule and the Nasdaq board-diversity disclosure requirement (2021) operate in the same direction. These mechanisms are documented on the mechanisms page under "Capital allocation" and "Reporting and accreditation."

The dataset's corporate-leadership entries cluster in two periods. The 2012–2014 wave saw Ginni Rometty take the IBM CEO role (2012), Marissa Mayer at Yahoo (2012), Marillyn Hewson at Lockheed Martin and Phebe Novakovic at General Dynamics (both 2013), Mary Barra at General Motors and Lisa Su at AMD and Susan Wojcicki at YouTube (all 2014). The 2020–2021 second wave saw Carol Tomé at UPS (2020), Karen Lynch at CVS Health (2021), and Jane Fraser at Citigroup (2021). The first cluster predates the documented institutional-investor diversity policies; the second is contemporaneous with them.

The contrast — first cluster ahead of the documented mechanisms, second cluster contemporaneous — is the kind of structural fingerprint the dataset preserves without prescribing a single causal interpretation.